Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q2 2026 · 10-Q
Revenue$63.69M$63.69M+33.7% vs Q2 2025 Net Income$48.51M$48.51M+900.8% vs Q2 2025 EPS Diluted$2.22$2.22+825.0% vs Q2 2025 Operating Income$8,591,000+1.7% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$23,992,000+53.9% Margins · derivedOperating margin13.5%−4.2 pt vs Q2 2025
Net margin76.2%+66.0 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 7, 2026 · 38 d after period end